期刊论文详细信息
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 卷:76
Raising the Evidentiary Bar for Guideline Recommendations for TAVR JACC Review Topic of the Week
Review
Kaul, Sanjay1,2 
[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Cardiol, Los Angeles, CA 90048 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词: clinical trials;    guidelines;    evidence;    TAVR;    SAVR;   
DOI  :  10.1016/j.jacc.2020.05.085
来源: Elsevier
PDF
【 摘 要 】

On August 16, 2019, the U.S. Food and Drug Administration approved expanding the indication for transcatheter aortic valve replacement (TAVR) to low-risk patients with symptomatic severe aortic stenosis. The decision was based on the results of 2 pivotal trials that confirmed superiority (PARTNER [Placement of Aortic Transcatheter Valves] 3) or noninferiority (Evolut Low Risk [LR]) of TAVR as compared with SAVR at 1- and 2-year follow-up, respectively. As compared with intermediate-risk cohorts, the sample size in these trials was smaller and the total number of primary endpoint events was nearly 3 times as low (193 vs. 615). The total number of deaths from any cause or disabling stroke at 1 year in the low-risk cohorts was 62, which is substantially lower than the numbers in intermediate-, high-, and inoperable-risk cohorts. In Evolut LR, only 137 of 1,403 patients (9.8%) completed the 2-year follow-up, with 91.2% requiring modelbased imputation. Thus, the quantum of evidence is insufficient for endorsing TAVR as the preferred intervention for these patients. (C) 2020 by the American College of Cardiology Foundation.

【 授权许可】

Free   

【 预 览 】
附件列表
Files Size Format View
10_1016_j_jacc_2020_05_085.pdf 386KB PDF download
  文献评价指标  
  下载次数:10次 浏览次数:0次